611 related articles for article (PubMed ID: 31330984)
1. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
[TBL] [Abstract][Full Text] [Related]
3. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
[TBL] [Abstract][Full Text] [Related]
4. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor heteromerization on cell signaling when expressed in HEK-293 cells.
Al-Zaid B; Chacko S; Ezeamuzie CI; Bünemann M; Krasel C; Karimian T; Lanzerstorfer P; Al-Sabah S
Pharmacol Res Perspect; 2022 Oct; 10(5):e01013. PubMed ID: 36177761
[TBL] [Abstract][Full Text] [Related]
6. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
Wu Y; Ji T; Lv J; Wang Z
Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
[TBL] [Abstract][Full Text] [Related]
7. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
[TBL] [Abstract][Full Text] [Related]
8. Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking.
Roed SN; Nøhr AC; Wismann P; Iversen H; Bräuner-Osborne H; Knudsen SM; Waldhoer M
J Biol Chem; 2015 Jan; 290(2):1233-43. PubMed ID: 25451942
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.
Darbalaei S; Yuliantie E; Dai A; Chang R; Zhao P; Yang D; Wang MW; Sexton PM; Wootten D
Biochem Pharmacol; 2020 Oct; 180():114150. PubMed ID: 32682761
[TBL] [Abstract][Full Text] [Related]
10. Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors.
Moon MJ; Kim HY; Kim SG; Park J; Choi DS; Hwang JI; Seong JY
Mol Cells; 2010 Aug; 30(2):149-54. PubMed ID: 20799012
[TBL] [Abstract][Full Text] [Related]
11. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
[TBL] [Abstract][Full Text] [Related]
12. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
[TBL] [Abstract][Full Text] [Related]
13. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
Mayendraraj A; Rosenkilde MM; Gasbjerg LS
Peptides; 2022 May; 151():170749. PubMed ID: 35065096
[TBL] [Abstract][Full Text] [Related]
15. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.
Zhao F; Zhou Q; Cong Z; Hang K; Zou X; Zhang C; Chen Y; Dai A; Liang A; Ming Q; Wang M; Chen LN; Xu P; Chang R; Feng W; Xia T; Zhang Y; Wu B; Yang D; Zhao L; Xu HE; Wang MW
Nat Commun; 2022 Feb; 13(1):1057. PubMed ID: 35217653
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
[TBL] [Abstract][Full Text] [Related]
17. Selectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells.
Al-Sabah S; Al-Fulaij M; Ahmed HA
Eur J Pharmacol; 2014 Oct; 741():311-5. PubMed ID: 25179575
[TBL] [Abstract][Full Text] [Related]
18. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
19. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Coskun T; Urva S; Roell WC; Qu H; Loghin C; Moyers JS; O'Farrell LS; Briere DA; Sloop KW; Thomas MK; Pirro V; Wainscott DB; Willard FS; Abernathy M; Morford L; Du Y; Benson C; Gimeno RE; Haupt A; Milicevic Z
Cell Metab; 2022 Sep; 34(9):1234-1247.e9. PubMed ID: 35985340
[TBL] [Abstract][Full Text] [Related]
20. Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice.
Leuthardt AS; Boyle CN; Raun K; Lutz TA; John LM; Le Foll C
Eur J Pharmacol; 2023 Sep; 955():175912. PubMed ID: 37454968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
